Abstract
Twenty years ago, a National Consensus Conference on Tuberculosis (TB) recommended that the provinces and territories of Canada jointly declare a commitment to TB elimination with national coordination and assured funding, executed by a committee of federal and provincial/territorial representatives. Canada has committed to the global TB elimination targets set forth by the World Health Organization but lacks a coordinated response. In particular, with the exception of one published and implemented by Indigenous Services Canada, there has been no national monitoring and performance framework. Herein, we provide a commentary on the importance, to TB elimination in Canada, of developing such a framework. We invite a debate about whether more can and should be done to monitor and report for action at every jurisdictional level. Of utmost importance will be the need to achieve consensus from stakeholders about what is measured, among whom, how often, who collects and processes data, and how to respond to the successes and failures those data indicate. Insofar, as performance targets are well defined and implemented, national progress towards tuberculosis elimination should accelerate.
Keywords: Tuberculosis elimination, Public health, Performance indicators
Résumé
Il y a 20 ans, la Conférence nationale de concertation sur la tuberculose recommandait aux provinces et aux territoires du Canada de s’engager conjointement à mettre en œuvre un programme d’élimination de la tuberculose coordonné à l’échelle nationale et jouissant d’un financement garanti, exécuté par un comité de représentants des autorités fédérales, provinciales et territoriales. Le Canada souscrit aux cibles mondiales d’élimination de la tuberculose établies par l’Organisation mondiale de la santé, mais manque une réponse coordonnée. En particulier, sauf pour celui publié et mis en œuvre par Services aux Autochtones Canada, il n’y a aucun cadre national de suivi des résultats. Notre commentaire porte sur l’importance d’un tel cadre pour l’élimination de la tuberculose au Canada. Nous cherchons à engager un débat pour déterminer s’il est possible et souhaitable d’en faire plus pour assurer le suivi et le compte rendu des mesures prises à tout ordre de gouvernement. Il sera de la plus haute importance de parvenir à un consensus des acteurs sur ce qui est mesuré, par qui, à quelle fréquence, qui recueille et traite les données, et comment réagir aux réussites et aux échecs que ces données indiquent. Dans la mesure où les cibles de résultats sont bien définies et mises en œuvre, les progrès réalisés à l’échelle nationale en vue d’éliminer la tuberculose devraient s’accélérer.
Mots-clés: Élimination de la tuberculose, Santé publique, Suivi des résultats
Introduction
As a co-signatory to the World Health Organization End TB Strategy, Canada has a responsibility to meet certain country-specific TB elimination targets: “pre-elimination”—reaching 10 cases per million by 2035, and “elimination”—reaching 1 case per million by 2050 (The World Health Organization (WHO) 2014). Unfortunately, with the disease now confined, almost exclusively, to Indigenous peoples and foreign-born migrants who are poorly positioned to advocate for themselves, and the rate having stayed between 4 and 5 per 100,000 over the past 15 years, the chances of meeting these targets, without major programmatic changes, are virtually impossible.
Directives aimed at TB elimination are not new to Canada. Twenty years ago, a National Consensus Conference on TB recommended that the provinces and territories jointly declare a commitment to TB elimination with national coordination and assured funding, executed by a committee of federal and provincial/territorial representatives (Proceedings of the National Consensus Conference on Tuberculosis 1998). Collaboration across jurisdictions with a “national dimension” of monitoring has been implemented successfully elsewhere, notably in the United States (US); unfortunately, despite the recommendations of the consensus conference, it is still missing from Canada two decades later (Centers for Disease Control (CDC) and Prevention 2012; Lönnroth et al. 2015). A 2016 Blueprint for a Federated System of Public Health Surveillance in Canada published by the Pan-Canadian Public Health Network provides additional support in favour of, and a recent justification for, federally supported surveillance efforts and a framework for a way forward; as such, we should consider ourselves ready to act (Pan-Canadian Public Health Network 2016). In the following commentary, we provide a rationale for a TB-specific monitoring and performance framework, report on the scale of the challenge, and introduce the concept of program performance indicators applicable to Canada as a whole, its provinces, territories, and population groups.
Rationale
Canada is a large country with a relatively small population concentrated in its southern latitudes. Most (> 90%) cases of TB are among Indigenous peoples and the foreign-born (Tuberculosis in Canada 2016 Pre-release. Public Health Agency of Canada. Minister of Public Works and Government Services Canada 2018; Long et al. 2013). With respect to Indigenous cases, a south-north gradient of risk has emerged with the highest rates and greatest burden of disease now reported in the north (Long et al. 2013). With respect to the foreign-born cases, most are reported in major metropolitan areas. The TB stakeholder community is not large and is mostly concentrated in the major immigrant-receiving provinces of Quebec, Ontario, Alberta, and British Columbia. These realities suggest that for Canada to achieve the ambitious TB elimination targets set out by the WHO and to which it has committed, the community of TB stakeholders, nationally, should organize to develop a network of cross-jurisdictional expertise. In other words, the resources of all stakeholders should be pooled as provinces, territories, and relevant federal departments work together in support of a country-specific strategy aimed at reaching pre-elimination and elimination targets. Provider delays in the diagnosis and treatment of TB due to a lack of access, service, or expertise are a social injustice and continue to occur in First Nations and Inuit communities (Galloway 2018).
TB is a complex disease, and its management and care cuts across many jurisdictions. It is a notifiable disease in all provinces and territories under relevant Public Health Legislation. By agreement, provincial, territorial, and federal—Indigenous Services Canada (ISC)—TB control programs report their TB notification and treatment outcome data to the Public Health Agency of Canada (PHAC) who, in turn, produce a national, surveillance snapshot using the Canadian Tuberculosis Reporting System (CTBRS) (Tuberculosis in Canada 2016 Pre-release. Public Health Agency of Canada. Minister of Public Works and Government Services Canada 2018). Most health services, including public health, are provided and funded by provinces and territories while others—for example, to registered First Nations and some Inuit—are a federal responsibility; communication across jurisdictions is usually limited. To achieve TB elimination, coordinating surveillance efforts across these jurisdictions is essential, and requires assured and sustained political and financial support from the federal government.
It is not unreasonable to conclude that the remarkable success—reporting the lowest national TB incidence among G7 nations in 2016—the US has achieved is in part attributable to the monitoring and performance framework their Centers for Disease Control (CDC) developed some years ago: the National TB Indicators Project (NTIP) (Centers for Disease Control (CDC) and Prevention 2012). The aforementioned CTBRS is, similarly, a national repository of data from provincial/territorial TB notification forms, but Canada has heretofore not availed itself of the system as an operational tool in the cause of disease elimination. Current CTBRS data are not organized in such a way as to track key indicators by jurisdiction, or population group, nor are reports from this system up to date, with the last full Tuberculosis in Canada report published in 2012; the last pre-release is for 2016.
Scale of the challenge
The WHO TB elimination targets are not likely to be achieved without significant programmatic changes. The national rate of TB disease has virtually plateaued, with a relatively minor decline in incidence from 2000 to 2016 (Fig. 1 a). It has been estimated that once the foreign-born migrants contribute 70% or more of cases within a country, which is now the case in Canada, the rate of decline is not expected to exceed 2% per year without making changes to existing programs or reducing the prevalence of disease overseas (The World Health Organization (WHO) 2008). At this rate of progress, we will not meet the internationally established, and nationally supported TB elimination targets (Fig. 1 b). To meet pre-elimination targets, cases among both Indigenous peoples and the foreign-born have to decline by 95%, or 4.52% per annum corresponding to annual reductions in the incidence rate of 0.855 and 0.515 per 100,000 population, respectively (Fig. 1 c). Use of granular and up-to-date program performance indicators could help to identify key “sticking points”, which programs and communities could then use to generate solutions that accelerate elimination.
We recommend one possible indicator collection and management scenario: a committee of provincial, territorial, and federal representatives is struck with the mandate of adopting the WHO post-2015 global TB strategy principle of “government stewardship and accountability [at all levels] with monitoring and evaluation” (The World Health Organization (WHO) 2018). This committee of stakeholders and partners should meet annually to interpret findings, request additional analyses as needed, and make recommendations to improve program performance in each jurisdiction. Shared experience and expertise, from the community up, is understood to be to the benefit of all. As a tool of surveillance, the CTBRS would collect and organize data for each of the suggested jurisdictions and population groups with indicators coming from or added to existing forms (Active Case Report Form; Treatment Outcome Form). Other surveillance strategies are also possible.
Data not currently reported in the CTBRS, but which were approved as indicators in the Pan-Canadian Public Health Network Guidance for Tuberculosis Prevention and Control Programs in Canada, the First Nations and Inuit Health Branch, Monitoring and Surveillance Framework, and two published Provincial program evaluations (Alberta and Manitoba) such as the results of contact investigations, would need to continue to be collected and reported in such a manner as to protect privacy and confidentiality (Proceedings of the National Consensus Conference on Tuberculosis 1998; Health Canada: First Nations and Inuit Health Branch 2016; Long et al. 2015; Basham et al. 2018). We have provided a potentially useful framework of indicators in Table 1; some indicators currently exist, while others are new. Their validity and the suggested best practice targets are recognized to be open to debate. All provinces, territories, and relevant federal ministries will need to agree, recognizing collaborative action to be in the best interest of their own jurisdiction as well as nationally. Local and provincial/territorial capacity for reporting and responding to poor performance should improve through the development of a coordinated nexus of expertise.
Table 1.
Indicator | Target |
---|---|
Incidence* | |
• Incidence (National) | Rate of decline commensurate with 2035 pre-elimination goals |
• Incidence (on- and off-reserve First Nations) | |
• Incidence (Inuit Nunangat) | |
• Incidence (Atlantic Canada) | |
• Incidence (Quebec) | |
• Incidence (Ontario) | |
• Incidence (Manitoba/Saskatchewan) | |
• Incidence (Alberta/Northwest Territories) | |
• Incidence (British Columbia/Yukon) | |
Laboratory reporting | |
• Turn-around time (NAAT) | 6 days (4 days specimen collection and delivery; 2 days detection) |
• Turn-around time (Culture) | 25 days (4 days specimen collection and delivery; 21 days to grow)—78% |
• Proportion HIV tested | 95% |
• Proportion of culture-positive cases with DST | 100% |
• Proportion of culture-positive cases with genotyping | 100% |
for smear-positive pulmonary cases † | |
• Sputum culture and CXR, end of initial phase | 100% |
• Sputum culture and CXR, end of continuation phase | 100% |
Case management and treatment | |
• Proportion of pediatric cases (< 5 years) | < 5% |
• CB cases/w no past hx TB started on a minimum of 3 drugs | 100% |
• FB cases/w no past hx TB started on a minimum of 4 drugs | 100% |
• Proportion with TB-related death of preceding years’ cases | < 5% |
for smear-positive pulmonary cases | |
• Starting treatment within 72 h of NAAT | 90% |
• Complete treatment within 12 months | 95% |
Contact investigations | |
• Close contacts of smear-positive pulmonary cases: | |
Proportion completely assessed < 5 years of age | 100% |
Proportion completely assessed ≥ 5 years of age | 80% |
• Close contacts with new positive TST/TST conversion: | |
Proportion recommended TX LTBI < 5 years of age | 100% |
Proportion recommended TX LTBI ≥ 5 years of age | 100% |
• Close contacts recommended TX LTBI: | |
Proportion who start treatment < 5 years of age | 100% |
Proportion who start treatment ≥ 5 years of age | 80% |
• Close contacts accepting TX LTBI: | |
Proportion who complete treatment < 5 years of age | 100% |
Proportion who complete treatment ≥ 5 years of age | 80% |
IRCC referrals | |
• Proportion who initiate examination within 30 days of notification | 100% |
• Proportion completing examination within 90 days of notification | 100% |
• Proportion of IRCC referrals recommended TX LTBI who accept | 90% |
• Proportion of IRCC referrals accepting TX LTBI who complete | 90% |
CTBRS reporting | |
• Active TB case report form (last full year) complete | 100% |
• Treatment outcome form (next to last full year) complete | 100% |
NAAT nucleic acid amplification test, DST drug susceptibility testing, CXR chest x-ray, CB Canadian-born, FB foreign-born, TX treatment, LTBI latent tuberculosis infection, IRCC Immigration Refugee and Citizenship Canada, CTBRS Canadian Tuberculosis Reporting System
*The proposed groupings take into account persons at risk, populations, existing organizational structures, and relationships
†The initial phase of treatment refers to an intensive three-four drug treatment regimen that lasts 2 months; the continuation phase lasts 4–7 months in fully susceptible cases and is usually a two-drug regimen
The NTIP provides individualized reports back to US states for monitoring, review, and progress as well as for justifying the provision of federal support to meet objectives (Centers for Disease Control (CDC) and Prevention 2012). While national surveillance is not an intervention that can be systematically evaluated, there is strong evidence in support of individual indicators monitored by their program. The success of this US program, and proposals from other high-income, low-incidence nations to implement national TB monitoring systems, make a similar recommendation for Canada prudent.
Discussion
Surveillance and monitoring are “disease reporting for action”—actions that are flexible and modifiable in response to what the data are portraying through an integrated program of research, which “closes the loop … so that those who report information can see that the data are being used… which, in turn, improves reporting” (Henderson 1998). Functional surveillance and monitoring is necessary to meet the needs of people everywhere in Canada who are unjustly disadvantaged by TB.
Nationally, TB disease disproportionately affects persons with limited power, status, and financial means, notably the foreign-born and Indigenous peoples (Tanday 2017). It may be that because TB affects the “voiceless”, progress towards TB elimination in Canada has been slow (Tanday 2017). Many people at risk of developing TB disease find themselves at the crossroads of multiple jurisdictions; a nationally coordinated response to disease elimination would help ensure their care meets a standard, and is not delayed. The tools and expertise are at hand to eliminate TB disease, but they need to be thoughtfully implemented in order that we get back on track. Responding to suboptimal TB program performance to get where we are going can only be achieved insofar as we know where we currently are.
Acknowledgements
The authors of this manuscript would like to thank the research staff of the Tuberculosis Program Evaluation and Research Unit at the University of Alberta, and Dr. Edward Ellis for a critical review of its contents.
References
- Basham CA, Elias B, Fanning A, Cook C, Orr P. Performance measurement of a Canadian provincial tuberculosis programme: Manitoba, 2008–2012. IJTLD. 2018;22(4):437–443. doi: 10.5588/ijtld.17.0508. [DOI] [PubMed] [Google Scholar]
- Centers for Disease Control (CDC) and Prevention. (2012). CDC National Tuberculosis Indicators Project Fact Sheet, 2012 http://www.cdc.gov/tb/publications/factsheets/statistics/NTIP.pdf. Accessed October 20, 2017.
- Galloway, G. (2018). Chief public health officer calls for tuberculosis eradication in the north. https://www.theglobeandmailcom/politics/article-chief-medical-officer-calls-for-eradication-of-tuberculosis-in-the/. Accessed March 23, 2018.
- Health Canada: First Nations and Inuit Health Branch. (2016): Monitoring and performance framework for tuberculosis programs for first nations on-reserve https://www.canada.ca/en/health-canada/services/publications/science-research-data/monitoring-performance-framework-tuberculosis-programs-first-nations-reserve-2015.html. Accessed October 21, 2017.
- Henderson DA. The challenge of eradication: lessons from past eradication campaigns. The International Journal of Tuberculosis and Lung Disease. 1998;2(9):S4–S8. [PubMed] [Google Scholar]
- Long R, Hoeppner V, Orr P, Ainslie M, King M, Abonyi S, Mayan M, Kunimoto D, Langlois-Klassen D, Heffernan C, Lau A, Menzies D. Marked disparity in the epidemiology of tuberculosis among aboriginal peoples on the Canadian prairies: the challenges and opportunities. Can Respir J. 2013;20(4):223–230. doi: 10.1155/2013/429496. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Long R, Heffernan C, Gao Z, Egedahl M, Talbot J. Do “virtual” and “outpatient” public health tuberculosis clinics perform equally well?: a program-wide evaluation in Alberta, Canada. PLoS One. 2015;10(12):e0144784. doi: 10.1371/journal.pone.0144784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928–952. doi: 10.1183/09031936.00214014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pan-Canadian Public Health Network. (2016). A blueprint for a federated system of public health surveillance in Canada. http://www.phn-rsp.ca/pubs/bfsph-psfsp-2016/index-eng.php. Accessed May 16, 2018.
- Proceedings of the National Consensus Conference on Tuberculosis. (1998). December 3-5, 1997. Canada Communicable Disease Report, 24(S2).
- Tanday S. Will we ever eliminate tuberculosis, the voiceless disease? The Lancet Respiratory Medicine. 2017;5(4):256–257. doi: 10.1016/S2213-2600(17)30080-2. [DOI] [PubMed] [Google Scholar]
- The World Health Organization (WHO). (2008). Global tuberculosis control: surveillance, planning, financing. http://apps.who.int/iris/handle/10665/43831. Accessed May 15, 2018.
- The World Health Organization (WHO). (2014). The end TB strategy. http://www.who.int/tb/post2015_strategy/en/ accessed October 10, 2017.
- The World Health Organization (WHO). (2018). The end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. http://www.who.int/tb/post2015_TBstrategy.pdf. Accessed May 15, 2018.
- Tuberculosis in Canada 2016 Pre-release. Public Health Agency of Canada. Minister of Public Works and Government Services Canada (2018). https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2018-44/issue-3-4-march-1-2018/article-1-tuberculosis-2016.html. Accessed March 23, 2018.